The Relationship between Smoking and Depression Post-Acute Coronary Syndrome

Current Cardiovascular Risk Reports

Volumn 5, Issue 6, 2011, Pages 510-518

  Busch, Andrew M ^a   Borrelli, Belinda ^a   Leventhal, Adam M ^b  

^a BROWN UNIVERSITY   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Acute coronary syndrome; Anhedonia; Depression; Smoking

Indexed keywords

AMFEBUTAMONE; PLACEBO; SEROTONIN UPTAKE INHIBITOR; VARENICLINE;

ABSTINENCE; ACUTE CORONARY SYNDROME; ANHEDONIA; BEHAVIOR; DEPRESSION; DRUG EFFICACY; HEART INFARCTION; HIGH RISK POPULATION; HUMAN; META ANALYSIS (TOPIC); NICOTINE REPLACEMENT THERAPY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; SMOKING; SMOKING CESSATION;

EID: 84873553734     PISSN: 19329520     EISSN: 19329563     Source Type: Journal    
DOI: 10.1007/s12170-011-0198-9     Document Type: Review

References (68)

1. Freedland KE, Carney RM, Skala JA. Depression and smoking in coronary heart disease. Psychosom Med. 2005; 67 Suppl 1: S42-6.
2. Thorndike AN, Rigotti NA. A tragic triad: coronary artery disease, nicotine addiction, and depression. Curr Opin Cardiol. 2009; 24: 447-53.
3. Anda RF, Williamson DF, Escobedo LG, et al. Depression and the dynamics of smoking. A national perspective. JAMA. 1990; 264: 1541-5.
4. Berlin I, Covey LS. Pre-cessation depressive mood predicts failure to quit smoking: the role of coping and personality traits. Addiction. 2006; 101: 1814-21.
5. Niaura R, Britt DM, Shadel WG, et al. Symptoms of depression and survival experience among three samples of smokers trying to quit. Psychol Addict Behav. 2001; 15: 13-7.
6. Berkman LF, Blumenthal J, Burg M, et al. Effects of treating depression and low perceived social support on clinical events after myocardial infarction: the Enhancing Recovery in Coronary Heart Disease Patients (ENRICHD) Randomized Trial. JAMA. 2003; 289: 3106-16.
7. Brothers BM, Borrelli B. Motivating Latino smokers to quit: does type of social support matter? Am J Health Promot. 2011; 25: S96-S102.
8. Hayes RB, Dunsiger S, Borrelli B. The influence of quality of life and depressed mood on smoking cessation among medically ill smokers. J Behav Med. 2010; 33: 209-18.
9. Borrelli B, Niaura R, Keuthen NJ, et al. Development of major depressive disorder during smoking-cessation treatment. J Clin Psychiatry. 1996; 57: 534-8.
10. Kahler CW, Brown RA, Ramsey SE, et al. Negative mood, depressive symptoms, and major depression after smoking cessation treatment in smokers with a history of major depressive disorder. J Abnorm Psychol. 2002; 111: 670-5.
11. Covey LS, Glassman AH, Stetner F. Major depression following smoking cessation. Am J Psychiatry. 1997; 154: 263-5.
12. Hughes JR. Depression during tobacco abstinence. Nicotine Tob Res. 2007; 9: 443-6.
13. Kahler CW, Spillane NS, Busch AM, Leventhal AM. Time-varying smoking abstinence predicts lower depressive symptoms following smoking cessation treatment. Nicotine Tob Res. 2011; 13: 146-50.
14. Shafer AB. Meta-analysis of the factor structures of four depression questionnaires: Beck, CES-D, Hamilton, and Zung. J Clin Psychol. 2006; 62: 123-46.
15. Watson D, Clark LA. Measurement and mismeasurement of mood: recurrent and emergent issues. J Pers Assess. 1997; 68: 267-96.
16. Davidson RJ, Ekman P, Saron CD, et al. Approach-withdrawal and cerebral asymmetry: emotional expression and brain physiology. J Pers Soc Psychol. 1990; 58: 330-41.
17. Ameringer KJ, Leventhal AM. Applying the tripartite model of anxiety and depression to cigarette smoking: an integrative review. Nicotine Tob Res. 2010; 12: 1183-94.
18. Leventhal AM, Ramsey SE, Brown RA, et al. Dimensions of depressive symptoms and smoking cessation. Nicotine Tob Res. 2008; 10: 507-17.
19. Zvolensky MJ, Bonn-Miller M, Bernstein A, Marshall E. Anxiety sensitivity and abstinence duration to smoking. J Ment Heal. 2006; 15: 659-70.
20. Cook J, Spring B, McChargue D, Doran N. Effects of anhedonia on days to relapse among smokers with a history of depression: a brief report. Nicotine Tob Res. 2010; 12: 978-82.
21. Japuntich SJ, Smith SS, Jorenby DE, et al. Depression predicts smoking early but not late in a quit attempt. Nicotine Tob Res. 2007; 9: 677-86.
22. Zvolensky MJ, Stewart SH, Vujanovic AA, et al. Anxiety sensitivity and anxiety and depressive symptoms in the prediction of early smoking lapse and relapse during smoking cessation treatment. Nicotine Tob Res. 2009; 11: 323-31.
23. Critchley JA, Capewell S. Mortality risk reduction associated with smoking cessation in patients with coronary heart disease: a systematic review. JAMA. 2003; 290: 86-97.
24. Dawood N, Vaccarino V, Reid KJ, et al. Predictors of smoking cessation after a myocardial infarction: the role of institutional smoking cessation programs in improving success. Arch Intern Med. 2008; 168: 1961-7.
25. Fiore MC, Jaen CR, Baker TB, et al. Treating tobacco use and dependence: 2008 update. Clinical Practice Guideline Rockville, MD: U. S. Department of Health and Human Services, Public Health Service; 2008.
26. Meine TJ, Patel MR, Washam JB, et al. Safety and effectiveness of transdermal nicotine patch in smokers admitted with acute coronary syndromes. Am J Cardiol. 2005; 95: 976-8.
27. Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction). Circulation. 2004; 110: e82-e292.
28. Rigotti NA, Pipe AL, Benowitz NL, et al. Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease: a randomized trial. Circulation. 2010; 121: 221-9.
29. Food and Drug Administration Drug Safety Communication: Chantix (varenicline) may increase the risk of certain cardiovascular adverse events in patients with cardiovascular disease. Available at: http://www. fda. gov/Drugs/DrugSafety/ucm259161. htm. Accessed August 2011.
30. Singh S, Loke YK, Spangler JG, Furberg CD. Risk of serious adverse cardiovascular events associated with varenicline: a systematic review and meta-analysis. CMAJ 2011.
31. Tonstad S, Farsang C, Klaene G, et al. Bupropion SR for smoking cessation in smokers with cardiovascular disease: a multicentre, randomised study. Eur Heart J. 2003; 24: 946-55.
32. Rigotti NA, Thorndike AN, Regan S, et al. Bupropion for smokers hospitalized with acute cardiovascular disease. Am J Med. 2006; 119: 1080-7.
33. Planer D, Lev I, Elitzur Y, et al. Bupropion for smoking cessation in patients with acute coronary syndrome. Arch Intern Med. 2011; 171: 1055-60.
34. Mohiuddin SM, Mooss AN, Hunter CB, et al. Intensive smoking cessation intervention reduces mortality in high-risk smokers with cardiovascular disease. Chest. 2007; 131: 446-52.
35. Rigotti NA, Munafo MR, Stead LF. Smoking cessation interventions for hospitalized smokers: a systematic review. Arch Intern Med. 2008; 168: 1950-60.
36. Thombs BD, Bass EB, Ford DE, et al. Prevalence of depression in survivors of acute myocardial infarction. J Gen Intern Med. 2006; 21: 30-8.
37. van Melle JP, de Jonge P, Spijkerman TA, et al. Prognostic association of depression following myocardial infarction with mortality and cardiovascular events: a meta-analysis. Psychosom Med. 2004; 66: 814-22.
38. Glassman AH, Bigger Jr JT, Gaffney M. Psychiatric characteristics associated with long-term mortality among 361 patients having an acute coronary syndrome and major depression: seven-year follow-up of SADHART participants. Arch Gen Psychiatry. 2009; 66: 1022-9.
39. Frasure-Smith N, Lesperance F, Talajic M. The impact of negative emotions on prognosis following myocardial infarction: is it more than depression? Health Psychol. 1995; 14: 388-98.
40. Lauzon C, Beck CA, Huynh T, et al. Depression and prognosis following hospital admission because of acute myocardial infarction. CMAJ. 2003; 168: 547-52.
41. Parker GB, Hilton TM, Walsh WF, et al. Timing is everything: the onset of depression and acute coronary syndrome outcome. Biol Psychiatry. 2008; 64: 660-6.
42. Thombs BD, Ziegelstein RC, Stewart DE, et al. Usefulness of persistent symptoms of depression to predict physical health status 12 months after an acute coronary syndrome. Am J Cardiol. 2008; 101: 15-9.
43. Burg MM, Lesperance F, Rieckmann N, et al. Treating persistent depressive symptoms in post-ACS patients: the project COPES phase-I randomized controlled trial. Contemp Clin Trials. 2008; 29: 231-40.
44. Pozuelo L, Tesar G, Zhang J, et al. Depression and heart disease: what do we know, and where are we headed? Cleve Clin J Med. 2009; 76: 59-70.
45. Ziegelstein RC, Fauerbach JA, Stevens SS, et al. Patients with depression are less likely to follow recommendations to reduce cardiac risk during recovery from a myocardial infarction. Arch Intern Med. 2000; 160: 1818-23.
46. Wong CK, Tang EW, Herbison P, et al. Pre-existent depression in the 2 weeks before an acute coronary syndrome can be associated with delayed presentation of the heart attack. QJM. 2008; 101: 137-44.
47. Mazza M, Lotrionte M, Biondi-Zoccai G, et al. Selective serotonin reuptake inhibitors provide significant lower re-hospitalization rates in patients recovering from acute coronary syndromes: evidence from a meta-analysis. J Psychopharmacol. 2010; 24: 1785-92.
48. • Davidson KW, Burg MM, Kronish IM, et al. Association of anhedonia with recurrent major adverse cardiac events and mortality 1 year after acute coronary syndrome. Arch Gen Psychiatry. 2010; 67: 480-8. This article showed that anhedonia was predictive of cardiac morbidity and all-cause mortality (combined) in the year following ACS after controlling for depressed mood. A major advantage of this study is that anhedonia and depressed mood were assessed using a structured clinical interview.
49. • Leroy M, Loas G, Perez-Diaz F. Anhedonia as predictor of clinical events after acute coronary syndromes: a 3-year prospective study. Compr Psychiatry. 2010; 51: 8-14. This article showed that both dimensional and categorically defined anhedonia predicted occurrence of severe cardiac and clinical events over 3 years post-ACS. In multivariate analyses, dimensional anhedonia was an independent predictor of poor cardiac outcomes whereas depressed mood was not.
50. Doyle F, Conroy R, McGee H, Delaney M. Depressive symptoms in persons with acute coronary syndrome: specific symptom scales and prognosis. J Psychosom Res. 2010; 68: 121-30.
51. Denollet J, Pedersen SS, Daemen J, et al. Reduced positive affect (anhedonia) predicts major clinical events following implantation of coronary-artery stents. J Intern Med. 2008; 263: 203-11.
52. Trockel M, Burg M, Jaffe A, et al. Smoking behavior postmyocardial infarction among ENRICHD trial participants: cognitive behavior therapy intervention for depression and low perceived social support compared with care as usual. Psychosom Med. 2008; 70: 875-82.
53. Thorndike AN, Regan S, McKool K, et al. Depressive symptoms and smoking cessation after hospitalization for cardiovascular disease. Arch Intern Med. 2008; 168: 186-91.
54. • Gerber Y, Koren-Morag N, Myers V, et al. Long-term predictors of smoking cessation in a cohort of myocardial infarction survivors: a longitudinal study. Eur J Cardiovasc Prev Rehabil. 2011. This article showed that depression at the time of ACS predicted persistent smoking during 13 years post-discharge after controlling for multiple covariates.
55. Havik OE, Maeland JG. Changes in smoking behavior after a myocardial infarction. Health Psychol. 1988; 7: 403-20.
56. McGee HM, Doyle F, Conroy RM, et al. Impact of briefly-assessed depression on secondary prevention outcomes after acute coronary syndrome: a one-year longitudinal survey. BMC Health Serv Res. 2006; 6: 9.
57. Perez GH, Nicolau JC, Romano BW, Laranjeira R. Depression: a predictor of smoking relapse in a 6-month follow-up after hospitalization for acute coronary syndrome. Eur J Cardiovasc Prev Rehabil. 2008; 15: 89-94.
58. Bjerkeset O, Nordahl HM, Mykletun A, et al. Anxiety and depression following myocardial infarction: gender differences in a 5-year prospective study. J Psychosom Res. 2005; 58: 153-61.
59. Kronish IM, Rieckmann N, Halm EA, et al. Persistent depression affects adherence to secondary prevention behaviors after acute coronary syndromes. J Gen Intern Med. 2006; 21: 1178-83.
60. Pelle AJ, Pedersen SS, Erdman RA, et al. Anhedonia is associated with poor health status and more somatic and cognitive symptoms in patients with coronary artery disease. Qual Life Res. 2011; 20: 643-51.
61. Lorenz RA, Whitley HP, McCoy EK. Safety of varenicline in patients with mental illness. Prim Psychiatry. 2010; 17: 60-6.
62. Mooney ME, Sofuoglu M. Bupropion for the treatment of nicotine withdrawal and craving. Expert Rev Neurother. 2006; 6: 965-81.
63. Brown RA, Kahler CW, Niaura R, et al. Cognitive-behavioral treatment for depression in smoking cessation. J Consult Clin Psychol. 2001; 69: 471-80.
64. Brown RA, Niaura R, Lloyd-Richardson EE, et al. Bupropion and cognitive-behavioral treatment for depression in smoking cessation. Nicotine Tob Res. 2007; 9: 721-30.
65. MacPherson L, Tull MT, Matusiewicz AK, et al. Randomized controlled trial of behavioral activation smoking cessation treatment for smokers with elevated depressive symptoms. J Consult Clin Psychol. 2010; 78: 55-61.
66. Brummett BH, Babyak MA, Siegler IC, et al. Effect of smoking and sedentary behavior on the association between depressive symptoms and mortality from coronary heart disease. Am J Cardiol. 2003; 92: 529-32.
67. Pagoto SL, Schneider K, Olendzki B, et al. Initial investigation of behavioral activation treatment for comorbid major depressive disorder and obesity. Psychother: Theory Res Pract Training. 2008; 45: 410-5.
68. Sturmey P. Behavioral activation is an evidence-based treatment for depression. Behav Modif. 2009; 33: 818-29.